Viracta Therapeutics (VIRX) Competitors $0.01 0.00 (-7.10%) As of 07/8/2025 03:38 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock VIRX vs. QLGN, ONCO, JAGX, VRAX, PTN, AWH, APVO, PCSA, ALZN, and CDTShould you be buying Viracta Therapeutics stock or one of its competitors? The main competitors of Viracta Therapeutics include Qualigen Therapeutics (QLGN), Onconetix (ONCO), Jaguar Animal Health (JAGX), Virax Biolabs Group (VRAX), Palatin Technologies (PTN), Aspira Women's Health (AWH), Aptevo Therapeutics (APVO), Heatwurx (PCSA), Alzamend Neuro (ALZN), and Conduit Pharmaceuticals (CDT). These companies are all part of the "pharmaceutical products" industry. Viracta Therapeutics vs. Its Competitors Qualigen Therapeutics Onconetix Jaguar Animal Health Virax Biolabs Group Palatin Technologies Aspira Women's Health Aptevo Therapeutics Heatwurx Alzamend Neuro Conduit Pharmaceuticals Viracta Therapeutics (NASDAQ:VIRX) and Qualigen Therapeutics (NASDAQ:QLGN) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, analyst recommendations, media sentiment, earnings, profitability, institutional ownership, dividends and risk. Which has more volatility and risk, VIRX or QLGN? Viracta Therapeutics has a beta of 1.06, suggesting that its stock price is 6% more volatile than the S&P 500. Comparatively, Qualigen Therapeutics has a beta of 0.03, suggesting that its stock price is 97% less volatile than the S&P 500. Do analysts prefer VIRX or QLGN? Viracta Therapeutics currently has a consensus price target of $1.75, suggesting a potential upside of 12,052.78%. Given Viracta Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Viracta Therapeutics is more favorable than Qualigen Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Viracta Therapeutics 0 Sell rating(s) 2 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.33Qualigen Therapeutics 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Do insiders and institutionals hold more shares of VIRX or QLGN? 31.4% of Viracta Therapeutics shares are owned by institutional investors. Comparatively, 3.2% of Qualigen Therapeutics shares are owned by institutional investors. 10.7% of Viracta Therapeutics shares are owned by company insiders. Comparatively, 1.8% of Qualigen Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term. Does the media favor VIRX or QLGN? In the previous week, Viracta Therapeutics' average media sentiment score of 0.00 equaled Qualigen Therapeutics'average media sentiment score. Company Overall Sentiment Viracta Therapeutics Neutral Qualigen Therapeutics Neutral Which has higher valuation and earnings, VIRX or QLGN? Qualigen Therapeutics has higher revenue and earnings than Viracta Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioViracta TherapeuticsN/AN/A-$51.06M-$1.10-0.01Qualigen Therapeutics$4.98M1.13-$6.26MN/AN/A Is VIRX or QLGN more profitable? Qualigen Therapeutics' return on equity of 0.00% beat Viracta Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Viracta TherapeuticsN/A -1,899.61% -114.21% Qualigen Therapeutics N/A N/A N/A SummaryViracta Therapeutics beats Qualigen Therapeutics on 6 of the 10 factors compared between the two stocks. Get Viracta Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for VIRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding VIRX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VIRX vs. The Competition Export to ExcelMetricViracta TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$572K$780.02M$5.47B$8.95BDividend YieldN/A4.84%5.25%4.06%P/E Ratio-0.011.0927.0020.10Price / SalesN/A230.52435.75120.29Price / CashN/A23.4436.8257.86Price / Book0.046.137.985.56Net Income-$51.06M-$27.85M$3.16B$248.40M7 Day PerformanceN/A0.67%2.40%4.67%1 Month PerformanceN/A8.48%2.19%6.64%1 Year PerformanceN/A6.72%33.82%21.31% Viracta Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VIRXViracta Therapeutics2.1039 of 5 stars$0.01-7.1%$1.75+12,052.8%-97.0%$572KN/A-0.0120QLGNQualigen TherapeuticsN/A$3.41-3.9%N/A-75.5%$2.61M$4.98M0.0050Gap UpONCOOnconetix0.288 of 5 stars$4.77-1.2%N/A-99.1%$2.57M$2.52M0.0012Positive NewsJAGXJaguar Animal Health2.0844 of 5 stars$2.52+0.8%$60.00+2,281.0%-97.4%$2.55M$11.69M0.0050VRAXVirax Biolabs Group2.8416 of 5 stars$0.79+1.5%$3.00+278.9%-27.8%$2.52M$160K0.005Positive NewsPTNPalatin TechnologiesN/A$0.09-44.6%N/AN/A$2.45M$350K-0.0630Gap DownHigh Trading VolumeAWHAspira Women's Health0.9028 of 5 stars$0.08-12.5%$5.50+6,607.3%-93.4%$2.44M$9.18M-0.07110High Trading VolumeAPVOAptevo Therapeutics2.0968 of 5 stars$3.05-1.0%$219,040.00+7,181,539.3%-100.0%$2.33M$3.11M0.0050PCSAHeatwurx3.7698 of 5 stars$0.21+4.5%$2.00+875.6%-86.8%$2.33MN/A-0.0720ALZNAlzamend Neuro2.2331 of 5 stars$2.91+0.3%$180.00+6,085.6%-92.9%$2.32MN/A0.004News CoveragePositive NewsCDTConduit PharmaceuticalsN/A$2.76-4.2%N/A-99.7%$2.30MN/A-0.013News CoverageHigh Trading Volume Related Companies and Tools Related Companies QLGN Alternatives ONCO Alternatives JAGX Alternatives VRAX Alternatives PTN Alternatives AWH Alternatives APVO Alternatives PCSA Alternatives ALZN Alternatives CDT Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VIRX) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Viracta Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Viracta Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
